<?xml version='1.0' encoding='utf-8'?>
<document id="22910806"><sentence text="Exposure to potentially dangerous drug-drug interactions involving antipsychotics." /><sentence text="Antipsychotic drug therapy is the cornerstone of treatment of persons with schizophrenia" /><sentence text=" Because most antipsychotics are metabolized by the hepatic cytochrome P450 system, concomitant use of an antipsychotic and medications that are competitively metabolized by the same system may cause a potentially harmful drug-drug interaction" /><sentence text=" This study used a large state's Medicaid claims database to examine the proportion of patients exposed to such interactions and the risk factors associated with exposure" /><sentence text="" /><sentence text="Claims from January 2000 through December 2003 for adult patients with a diagnosis of schizophrenia and at least one prescription for an antipsychotic (N=27,909) were examined for pairs of medications identified as potentially causing moderate or severe adverse drug effects" /><sentence text=" Logistic regression models were estimated to determine potential risk factors associated with exposure to the interaction pairs" /><sentence text="" /><sentence text="A total of 6,417 (23%) patients were exposed to 14,213 potentially harmful interactions; 4,725 patients had at least one exposure from the same pharmacy, and 4,032 patients were exposed by the same physician" /><sentence text=" The greatest number of exposures (N=1,353) to potentially harmful combinations involved olanzapine and haloperidol"><entity charOffset="89-99" id="DDI-PubMed.22910806.s10.e0" text="olanzapine" /><entity charOffset="104-115" id="DDI-PubMed.22910806.s10.e1" text="haloperidol" /><pair ddi="false" e1="DDI-PubMed.22910806.s10.e0" e2="DDI-PubMed.22910806.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22910806.s10.e0" e2="DDI-PubMed.22910806.s10.e1" /></sentence><sentence text=" Patients prescribed risperidone were most likely to be exposed to an interaction (13"><entity charOffset="21-32" id="DDI-PubMed.22910806.s11.e0" text="risperidone" /></sentence><sentence text="1%), followed by patients prescribed olanzapine (10"><entity charOffset="37-47" id="DDI-PubMed.22910806.s12.e0" text="olanzapine" /></sentence><sentence text="3%), quetiapine (3"><entity charOffset="5-15" id="DDI-PubMed.22910806.s13.e0" text="quetiapine" /></sentence><sentence text="3%), and clozapine (3"><entity charOffset="9-18" id="DDI-PubMed.22910806.s14.e0" text="clozapine" /></sentence><sentence text="2%)" /><sentence text=" A higher risk of exposure was associated with being female (odds ratio [OR]=" /><sentence text="94), being white (OR=1" /><sentence text="43), having depression (OR=1" /><sentence text="21), or having impulse-control disorder (OR=1" /><sentence text="98)" /><sentence text="" /><sentence text="Interventions by physicians and pharmacies to reduce the prescribing and dispensing of potentially harmful pairs of medications to patients with schizophrenia are recommended" /><sentence text="" /></document>